MannKind Corp (MNKD.OQ)
11 Dec 2017
* Mannkind Corp - extended maturity of $10 million of deerfield facility to Jan 15, 2018 and allowed for such principal to be converted into common stock
* Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)
* Mannkind corp - on august 4, board resolved to voluntary delist its common stock from tel aviv stock exchange ltd - sec filing
* Q2 revenue $2.2 million Source text for Eikon: Further company coverage:
* MannKind and One Drop partner to launch the A-one clinical trial
* MannKind Corp - Steven Binder has joined company as its Chief Financial Officer Source text for Eikon: Further company coverage:
BRIEF-Mannkind files for offer and sale of up to 7.3 mln shares of common stock issuable upon exercise of Series A common stock purchase warrants
* Mannkind Corp files for offer and sale of up to 7.3 million shares of common stock issuable upon exercise of Series A common stock purchase warrants
* Mannkind-Deerfield to amend terms of minimum liquidity covenant such that each month from October to December, company must maintain at least $10 million of cash & cash equivalents
* Mannkind- delivered funding request notification to Mann Group pursuant to terms of Mann Group loan
- MannKind: Afrezza Scripts Recover From Holiday Week - What Investors Need To Know
- MannKind's Afrezza Scripts Dip On Holiday Week - Share Authorization Vote On Deck
- Could The FDA's Less Stringent Regulations Help MannKind?
- MannKind: Afrezza Scripts And Revenue Rising - Is It Enough?
- An Integrated BioSci Research On MannKind Corporation: How To Unlock Value?
- MannKind: Afrezza Scripts Remain Flat As Holiday Season Approaches